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ina.We prospectively treated 80 patients with relapse of malignancy or secondary myelodysplasia after autologous
hematopoietic cell transplantation (AHCT) with allogeneic HCT (allo-HCT) using a reduced-intensity condi-
tioning regimen of fludarabine 150 mg/m2 plus intravenous busulfan 6.4 mg/kg. Both matched sibling (MSD) and
unrelated donors (MUD) were allowed. Patients transplanted from MUD donors received more intensive
graft-versus-host disease (GVHD) prophylaxis, including rabbit antithymocyte globulin (ATG) 10 mg/kg, myco-
phenolate mofetil, and an extended schedule of tacrolimus. With a median follow-up of 3.1 years (0.9-5.8),
treatment-related mortality (TRM) at 6 months and 2 years was 8% and 23%, respectively. Neither TRM
nor the rates of acute GVHD (aGVHD) were different in those with sibling or MUD donors. Donor CD3
cell chimerism .90% at day 130 was achieved more often in patients with MUD than with matched sibling
donors, 70% versus 23% (P\ .0001). Median event-free suvival was higher in patients who achieved early
full donor chimerism (14.2 versus 8 months, P 5 .0395). Allo-HCTusing this reduced-intensity conditioning
regimen can be performedwith low TRM in patients who have received a prior AHCT. Efforts to improve early
donor CD3 chimerism may improve event-free survival.
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AHCT [1-7]. However, the use of traditional
myeloablative (MA) allo-HCT for this purpose has
been associated with high rates of treatment-related
mortality (TRM), which has limited its use [3-5,7].
Studies of reduced-intensity conditioning (RIC) allo-
HCT from selected groups have suggested that such
transplants may be associated with lower and more
acceptable rates of TRM when used following AHCT
[8-10]. However, it has not been demonstrated that
low TRM can be achieved in the context of a multi-
institutional national cooperative group. We hypothe-
sized that RIC allo-HCT would produce a low TRM
following failure of AHCT in the context of a coopera-
tive group.We also hypothesized that the use of a more
aggressive regimen for the prophylaxis of graft-versus-
host disease (GVHD) in patients with matched unre-
lated donors (MUDs) would result in a similar low
rate of TRM in these patients when compared to pa-
tients with HLA-identical matched sibling donors
(MSDs). A Cancer and Leukemia Group B (CALGB)
study 100002 tested these hypotheses, and the results
of this trial are reported here.PATIENTS AND METHODS
The study was performed prospectively at approved
allogeneic transplant centers of the Cancer and Leuke-
mia Group B (CALGB).
Eligibility
Patients were required to have developed recur-
rence of malignancy or secondary MDS/AML .6
months following AHCT for a hematologic malig-
nancy. Other eligibility criteria included: age \70
years, HIV-negative, nonpregnant and nonnursing,
satisfactory vital organ function (left ventrical ejection
fraction [LVEF] $30%, diffusion lung capacity for
carbon monoxide [DLCO] .40% predicted, creati-
nine clearance$40 mL/min, bilirubin/AST#3  up-
per limit of normal). Patients were required to have
either an HLA MSD or a 10/10 [HLA-A, -B, -C,
-DRB1, and -DQB1] allele MUD. Patients provided
informed consent and the study was approved by the
Cancer Treatment Evaluation Program (CTEP) of
the National Cancer Institute and the institutional
review board (IRB) of each participating center.
Treatment Regimen
The preparative regimen consisted of fludarabine 30
mg/m2/day intravenously (i.v.) 5days (day27 through
23) and busulfan (Bu) 0.8 mg/kg every 6 hours i.v.  2
days (days 24, 23). MUD patients also received rabbit
antithymocyte globulin (ATG) (Thymoglobulin;
Genzyme, Cambridge, MA, USA) at a dose of 2.5 mg/
kg/day  4 days (day 24 through 21). Granulocyte-colony stimulating factor (G-CSF) mobilized donor
peripheral blood (PB) hematopoietic cells (CD341 cell
dose 2-8  106/kg) were infused on day 0. G-CSF 5
mg/kg/daywas administered fromday17 until the abso-
lute neutrophil count (ANC) recovered to $1000/mL.
GVHD prophylaxis consisted of tacrolimus twice daily
(starting on day 21 to maintain levels at 5-10 ng/mL
and then tapered as tolerated starting day 190 for
MSD patients and day 1180 for MUD patients) and
methotrexate 5 mg/m2 i.v. (day 11, 13, and 16 for
MSD patients and day 11, 13, 16, and 111 for
MUD patients). Patients with MUD also received my-
cophenylate mofetil 15 mg/kg orally twice daily from
day22 through day160.
Supportive care recommendations included acyclovir
200-400 mg 3 times daily, cotrimoxazole twice weekly,
and fluconazole (200-400 mg/day) or voriconazole 200-
300 mg twice daily and weekly cytomegalovirus (CMV)
monitoring with preemptive therapy through day 1100
(or longer in patients with active GVHD).
Donor lymphocyte infusions (DLIs) were allowed
only for persistent or progressive malignancy. Patients
receiving DLI were required to have no active GVHD
and to have ceased immunosuppressive therapy for
.30 days. MSD patients received escalating dose
DLI at 8 week intervals according to the following
schedule: 1  107, 5  107, 5  107 CD31 cells/kg.
MUD patients received the following doses also at 8-
week intervals: 5 106, 1 107, 5 107 CD31 cell/kg.Evaluations
Patients were evaluated for toxicity and GVHD
twice weekly through day 128, weekly through day
1100 and monthly through day 1365. Restaging of
malignancy was performed every 3 months through 3
years post-allo-HTand every 6months thereafter. Cen-
tralized chimerism studies were performed at the HLA
laboratory at University of California, San Francisco
by Dr Lee Ann Baxter-Lowe. Chimerism was analyzed
separately in PB T cells, and myeloid-origin cells using
a PCR-based method that routinely achieved 1% sensi-
tivity. CD3 and CD14/15 cells were selected from PB
mononuclear cells (Ficoll-Hypaque fraction) usingMil-
tenyi magnetic particles (Miltenyi Biotec, Bergisch
Gladbach, Germany). The purity of each cell subset
was determined by flow cytometry. Two short tandem
repeat (STR) loci were amplified for each donor-
recipient pair (selected from VWF, D21S11, D18S51,
D16S539, PENTA D, D3S1358, FGA, D7S820,
D2S1338, D10S2325, D12S391, SE33, and PENTA
E). Amplicons were separated using an automated nu-
cleotide sequencer (ABI 3100 Applied Biosystems, Fos-
ter City, CA,USA) and the quantity of each informative
allele from duplicate samples was determined using
GeneMapper fragment analysis software (Applied Bio-
systems). Every assay included sensitivity controls
560 Biol Blood Marrow Transplant 17:558-565, 2011A. Bashey et al.(mixtures of donor and recipient DNA) and if preferen-
tial amplification was observed, a standard curve was
also included to normalize the data [11]. Full-donor chi-
merismwas defined as.90%of cells being of donor or-
igin at the time point tested (days 130, 160, 190, and
1180).Statistical Considerations
Patient registration and data collection were man-
aged by the CALGB Statistical Center. Data quality
was ensured by careful review of data by CALGB
Statistical Center staff and by the study chairperson.
Statistical analyses were performed by CALGB statis-
ticians. The study was designed as a phase II trial with
a sample size of 80 patients to assess the null hypothesis
that TRM at 6 months post-allo-HCT would exceed
25%. TRM was defined as death from any cause in
the absence of disease progression/relapse. A 4-stage
design was utilized with stopping rules based upon
the number of patients who experience TRM at each
stage. The study was designed so as to have a power
of 0.92 at the 1-sided 0.08 level. TRM was calculated
according to the cumulative incidence method. Re-
lapse was treated as a competing risk. Descriptive sta-
tistics were used to determine patient characteristics.
Time-to-event distributions were estimated using
the Kaplan-Meier method. Overall survival (OS) was
determined from the date of allo-HCT, whereas
event-free survival (EFS) was defined as time to death
or progression of malignancy. Time-to-event distribu-
tions were compared using the log-rank test. Fisher’s
exact test was used to compare the rate of complica-
tions between MSD and MUD patients.Table 1. Patient Characteristics
MSD (n 5 37)
Characteristic n %
Race
White 30 81.1
Hispanic 2 5.4
Black 3 8.1
Asian 2 5.4
Male 26 70.3
Diagnosis
NHL 15 40.5
HD 8 21.6
MM 6 16.2
CLL 0 0.0
de novo AML 4 10.8
de novo MDS 0 0.0
Therapy related AML/MDS 4 10.8
Age
Median, range 51 24-70
Years from prior transplant
Median, range 2.1 0.6-17.3
MSD indicatesHLA-identical matched sibling donor; MUD,matched unrelated d
CLL, chronic lymphocytic leukemia; MM, multiple myeloma; MDS, myelodysplaAudit Information
As part of the quality assurance program of the
CALGB, members of the Audit Committee visit all
participating institutions at least onceevery3years to re-
view source documents. The auditors verify compliance
with federal regulations and protocol requirements,
including those pertaining to eligibility, treatment, ad-
verse events, tumor response, and outcome in a sample
of protocols at each institution. Such on-site review of
medical records was performed for a subgroup of 22
(27%) of the 82 patients under this study.RESULTS
Patient Characteristics
Eighty-two patients were registered on this study
from 11 CALGB allogeneic transplant centers. Two
patients were withdrawn between registration and initi-
ation of study treatment, and 80 patientswere treated on
this study. Their characteristics are shown in Table 1.
Median follow-up from the date of registration on study
is 3.1 years (range 0.9-5.8 years).
TRM, OS, and EFS
All living patients had .6-months follow-up from
allo-HCT at the time of analysis. Seven of 80 patients
died of TRM within 6 months (8.8%). The estimated
cumulative probabilities (with 95% confidence inter-
vals) of TRM for all patients at 6 months and 2 years
were 8% (2%-14%) and 23% (14%-32%), respec-
tively (Figure 1A). The corresponding estimated
cumulative probabilities of TRM (with 95% confi-
dence intervals [CIs]) for the MSD and MUD patients
were 3% (0%-8%), 12% (0%-24%), respectively, atDonor Type
MUD (n 5 43) All (n 5 80)
n % n %
43 100.0 73 91.2
0 0.0 2 2.5
0 0.0 3 3.8
0 0.0 2 2.5
23 53.5 49 61.2
11 25.6 26 32.5
9 20.9 17 21.2
10 23.3 16 20.0
1 2.3 1 1.2
4 9.3 8 10.0
1 2.3 1 1.2
7 16.3 11 13.8
48 17-67 51 17-70
2.7 0.6-6.8 2.4 0.6-17.3
onor; NHL, non-Hodgkin lymphoma; AML, acutemyelogenous leukemia;
stic syndrome; HD, Hodgkin disease.
Cumulative Incidence of TRM
Years
Pr
ob
ab
ilit
y 
of
 T
RM
0 1 2 3 4 5 6
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
All Patients N=80 Events=20
Cumulative Incidence of TRM 
 By Donor Type
Years
Pr
ob
ab
ilit
y 
of
 T
RM
0 1 2 3 4 5 6
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
MSD N=37 Events=11
MUD N=43 Events=9
Figure 1. Treatment-related mortality (TRM). The cumulative esti-
mated probability and 95% confidence intervals of TRM is shown. (A)
All patients. (B) TRM for HLA-identical sibling donor patients and
matched-unrelated donor patients.
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spectively, at 2 years (P 5 NS) (Figure 1B).
Reported causes of death were: infection 6,GVHD
6, pneumonitis/respiratory failure 4, coagulopathy 1,
renal failure 1, cerebral ischemia 1, and posttransplant
lymphoproliferative disease 1.
The estimated probability of OS at was 84% (95%
CI 74%-90%) at 6 months and 47% (36%-58%) at
two years, respectively (Figure 2A). EFS was 62%
(51%-72%) at 6 months and 29% (20%-40%) at two
years, respectively (Figure 2C). Neither median sur-
vival (1.93 years versus 1.69 years) nor median EFS
(0.96 versus 0.54 years) was significantly different for
MSD and MUD patients (Figure 2B and D).GVHD and Infections
The cumulative incidence of acute and chronic
GVHD (aGVHD, cGVHD) is shown in Figure 3. The
cumulative incidence of aGVHD at 1 year was 44%
(95% CI 33%-55%). It was not significantly different
between MSD and MUD patients: 55% (35%-67%)versus 37% (25%-52%), respectively. The correspond-
ing cumulative incidence of severe (grades III and IV)
aGVHD at 1 year was 15% (7%-23%) for all patients
and 22% (9%-35%) versus 9% (0%-18%), respectively,
for MSD and MUD patient (P 5 NS). The cumulative
incidence of cGVHD at 2 years was 45% (34%-56%)
for all patients and was significantly higher for MSD
versus MUD patients: 59% (43%-75%) versus 33%
(19%-47%) (P 5 .015). The corresponding cumulative
incidence of extensive cGVHD at 2 years was 23%
(14%-32%) in all patients and was significantly higher
in MSD versus MUD patients: 36% (20%-52%) versus
12% (2%-22%), respectively (P5 .009).
The cumulative incidence of reported viral, bacte-
rial, and fungal infections was not statistically different
between MSD and MUD patients (65% versus 74%).
Chimerism
Chimerism was separately analyzed for T cells
(CD31) and cells of myeloid origin (CD14/151) in
the PB at monthly time points following transplanta-
tion. The results of CD3 chimerism are shown in
Table 2. Patients transplanted from an MSD were sig-
nificantly less likely to achieve full donor CD31 cell
chimerism than MUD patients at day 130 and day
190 (P\ .0001 and P5 .017, respectively). However,
there was no significant difference at later time points.
Full-donor chimerism in PB myeloid cells (CD14/
151) was achieved in 94% of MSD patients and 97%
of MUD patients on day 130 and by 94% of both
groups by day 190. Patients who achieved full donor
CD3 chimerism at day 130 post-allo-HCT had a sig-
nificantly better EFS (P 5 .0395, log-rank test) than
patients who failed to achieve full donor CD3 chime-
rism by this time point (median EFS 14.2 months ver-
sus 8 months, EFS at 2 years 38% versus 23%)
(Figure 4). The corresponding values for median
OS were 36 months versus 15.6 months respectively
(P 5 NS).
Donor Lymphocyte Infusions
Nine patients received a total of 18 DLIs for pro-
gression/persistence of malignancy. Two patients
(Hodgkin disease [HD], chronic lymphocytic leuke-
mia [CLL]) responded by achieving a complete remis-
sion (CR) after 1 and 3 DLIs that remains durable at
the time of reporting. Seven patients (2HD, 5multiple
myeloma [MM]) showed no response or progressive
malignancy following DLI.DISCUSSION
This study assessed the tolerability of RIC allo-
HCT to treat RM or MDS/AML developing after
AHCT for hematologic malignancies. Although pa-
tients with RM following AHCT may theoretically
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562 Biol Blood Marrow Transplant 17:558-565, 2011A. Bashey et al.face a different risk of recurrent malignancy following
allo-HCT than patients with MDS/AML following
AHCT, they face similar questions regarding the
tolerability of allo-HCT following a prior AHCT.
They were therefore included in this study. Consistent
with our hypothesis, the estimated probability of
TRMwas only 8% at 6 months and 23% at 24 months.
Although there was a suggestion of a higher TRM in
MUDpatients at 6months (estimated cumulative prob-
ability 12%versus 3%,P5NS), theTRMat2 yearswas
not different between the donor types. These data sug-
gest that the use ofRIC can abrogate the highTRM tra-
ditionally seen whenMA allo-HCTwas used following
failure of AHCT. Furthermore, our data suggest that
low TRM can be achieved within the context of
a multi-institutional cooperative group trial. Whereas
it is likely that the reduced intensity of the preparative
regimen is the predominant cause of the low TRM
seen, advances in supportive care that have occurred
since the originally reported studies of allo-HCT fol-
lowing failure of AHCT may also have contributed. Insupport of this suggestion, a recent retrospective analy-
sis ofMA allo-HCTas second transplant for lymphoma
performed by the Center for International Blood and
Marrow Transplant Research (CIBMTR) demon-
strated a 3-year TRM of only 22% [12].
We also hypothesized that the use of a more
aggressive GVHD prophylaxis regimen in patients
receiving transplants from MUD would eliminate the
greater risk of aGVHD and cGVHD traditionally
reported for MUD transplants versus transplants from
MSD. To test this hypothesis we used only fully
matched unrelated donors (10 of 10 match at HLA-
A,- B, -C, -DRB1, and -DQ alleles), and HLA-
identical sibling donors in this study. As expected, the
incidence and severity of GVHD was not greater in
MUD transplant patients in our study. Indeed, the
incidence and severity of cGVHD was lower in MUD
patients than in MSD patients. In this respect, our
GVHD prophylaxis regimen for MUD patients may
have been overly aggressive. All MUD donors used
were fully matched. Several reports published since
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Figure 3. GVHD. The cumulative incidence of acute and chronic GVHD (aGVHD, cGVHD) by donor type is shown. (A) aGVHD, (B) severe (grades III
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pears to no increased incidence of GVHD or mortality
in patients receiving allele-matched MUD transplants
when compared to those transplanted from MSD
even when similar GVHD prophylaxis is used for the
2 groups [13-15]. Indeed, the higher risk of GVHD
and mortality seen in older comparisons of MUD
versus MSD donor transplants may be related to
allele-level HLA-incompatibility between MUD and
recipient, which was undetected by the serological
and low-resolution typing used in those studies [16].
Chimerism was studied separately for PB T cells
and myeloid cells. This analysis revealed that the
RIC regimen used here (fludarabine and low-dose
Bu) results in full-donor chimerism in myeloid cells
at all time points following transplant in both MSD
and MUD patients. However, in the MSD patients
(in whom ATG was not used in the preparative regi-
men), relatively few patients achieved CD31 cell full-
donor chimerism (23% by day130). CD31 chimerism
improved at later time points following transplant such
that by day1120 and1180 62% and 81% ofMSD pa-
tients achieved full-donor CD31 cell chimerism. As
DLIs were not allowed for low-level CD31 chimerismin the absence of malignant progression in this study,
the lack of early full-donor CD31 cell chimerism
may have limited the graft-versus-malignancy effect
in these patients. On the other hand, it may have had
a protective effect against aGVHD. Other investiga-
tors have reported a delay in achievement of full donor
T cell chimerism when using Bu-based RIC regimens
[17-19]. Some reports have associated the failure to
achieve full-donor T cell chimerism at day 130 with
\2 prior chemotherapy regimens before allo-HCT
[17,19]. This pattern was seen in our study despite
the fact that all patients had .2 prior chemotherapy
regimens as well as a prior AHCT. The rate of early
full-donor T cell chimerism was also unrelated to the
interval between prior AHCT and the allo-HCT
(data not shown). The use of ATG in the preparative
regimen may be at least partly responsible for the
much higher rates of full-donor T cell chimerism for
MUD patients in our study. The ability of ATG to
augment the rates of donor T cell chimerism seen early
post allo-HCT has been previously described [20].
The impact of delayed early T cell chimerism seen in
the MSD patients in our study is unclear. Some inves-
tigators have associated such a delay with an increased
Table 2. CD3 Chimerism
MSD MUD Total
Day 30
#90% 27 (75.0%) 12 (30.0%) 39 (51.3%)
>90% 9 (23.1%) 28 (70.0%) 37 (48.7%)
Total 36 40 76
P-value <.0001
Day 60
#90% 20 (55.6%) 12 (33.3%) 32 (44.4%)
>90% 16 (44.4%) 24 (66.7%) 40 (55.6%)
Total 36 36 72
P-value .0962
Day 90
#90% 16 (50.0%) 6 (18.8%) 22 (34.4%)
>90% 16 (50.0%) 26 (81.2%) 42 (65.6%)
Total 32 32 64
P-value .0169
Day 120
#90% 11 (37.9%) 4 (16.0%) 15 (27.8%)
>90% 18 (62.1%) 21 (84.0%) 39 (72.2%)
Total 29 25 54
P-value .13
Day 180
#90% 4 (18.2%) 2 ( 4.8%) 6 (14.3%)
>90% 18 (81.2%) 18 (90.0%) 36 (85.7%)
Total 22 20 42
P-value .26
MSD indicates HLA identical matched sibling donor patients; MUD,
matched unrelated donor patients.
The number and percentage (in parenthesis) of patients who achieved
>90% donor-derived versus#90% donor-derived CD3+ cells in periph-
eral blood is shown at time points from day 30 through day 180 following
transplant.
564 Biol Blood Marrow Transplant 17:558-565, 2011A. Bashey et al.rate of relapse of malignancy [18,19], although others
have not found such an effect [17].We showed a signif-
icantly favorable effect of full-donor T cell chimerism
at day 130 on EFS in this study.
Although TRM was low as hypothesized in our
study, long-term EFS was disappointing (29% for
both MSD and MUD patients at 2 years). At the time
of reporting, 16 of the 80 patients transplanted on thisyrtnEydutSmorfsraeY
Pr
ob
ab
ilit
y
543210
0.
0
0.
2
0.
4
0.
6
0.
8
lavivruSeerF-tnevE
msiremihClluFylraEyB
%09=<
%09>
93=N
73=N
63=stnevE
52=stnevE
66.0=naideM
81.1=naideM
=erauqs-ihC
=eulav-p
42.4
5930.0
Figure 4. Effect of CD3 chimerism on EFS. EFS is shown for patients
who achieved .90% donor-derived CD31 cells in peripheral blood by
day 130 (dashed line) versus patients who achieved #90% donor-
derived CD31 cells (solid line).study are alive and free of malignancy. It is possible
that many of these patients may be cured. However,
measures to lower the rate of early relapse seen are
clearly necessary when designing follow-up studies in
this population. Options include the addition of low
dose ATG to improve early T cell chimerism in the
MSD patients, targeting a higher pharmacokinetically
directed dose of Bu in the preparative regimen, reduced
posttransplant GVHD prophylaxis, and maintenance
anticancer therapy in the posttransplant period.ACKNOWLEDGMENTS
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